Compounded Aseptic Medicines

A Voluntary Ex-Ante Transparency (VEAT) Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)

Source: Find a Tender
Type: Framework (Supply)
Duration: 3 year (est.)
Value: £85M

Sector: HEALTH
Published: 30 Jan 2024
Delivery: To 25 Mar 2027 (est.)
Deadline: n/a

Concepts

Location

Edinburgh

Geochart for 2 buyers and 6 suppliers

2 buyers

NHS National Services Scotland NSS Edinburgh

3 suppliers

Qualasept Corsham
Baxter Healthcare Berkshire
Ith Pharma London

Description

This Framework Agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland.

Lot Division

1	Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Atezolizumab Cetuximab Doxorubicin Epirubicin Infliximab (Inflectra®), (Remicade®), (Remsima®) Nivolumab Pembrolizumab Pertuzumab The Authority intends to awarded all presentations within this Lot to a single supplier.
2	Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Cyclophosphamide Fluorouracil Irinotecan Methotrexate Rituximab (Mabthera®), (Rixathon®), (Truxima®) The Authority intends to awarded all presentations within this Lot to a single supplier.
3	Compounded Aseptic Medicines Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, Bortezomib Carboplatin Cisplatin Docetaxel Gemcitabine Oxaliplatin Trastuzumab (Herceptin®), (Herzuma®) Vincristine The Authority intends to awarded all presentations within this Lot to a single supplier.
4	Compounded Aseptic Medicines - All Other Presentations upply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, The molecules included in this Lot are, Bevacizumab Cytarabine Infliximab (Zessly®) Insulin Methotrexate Natalizumab Nivolumab Paclitaxel Pemetrexed Tocilizumab Trastuzumab (Kanjinti®), (Ontruzant®) Trastuzumab Subcutaneous Vedolizumab Each product line will be treated as an individual Lot and awarded as an unranked multi-supplier framework.

Award Detail

1	Qualasept (Corsham) Compounded Aseptic Medicines Value: £1,012,575
2	Baxter Healthcare (Berkshire) Compounded Aseptic Medicines Value: £945,623
3	Baxter Healthcare (Berkshire) Compounded Aseptic Medicines - All Other Presentations Value: £3,956,458 [share] Awarded to group of suppliers.
4	Qualasept (Corsham) Compounded Aseptic Medicines - All Other Presentations Value: £3,956,458 [share] Awarded to group of suppliers.
5	Ith Pharma (London) Compounded Aseptic Medicines - All Other Presentations Value: £3,956,458 [share] Awarded to group of suppliers.
6	Baxter Healthcare (Berkshire) Compounded Aseptic Medicines Value: £15,384,611

CPV Codes

33600000 - Pharmaceutical products

Indicators

Legal Justification

This VEAT notice is to advise the need for modification to meet the additional demands of the Scottish Health and Social Care sector during the current Covid-19 pandemic and to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015

Other Information

The estimated value(s) of the Framework Agreement referred to in Section V.2.4 (comprising three (3) Lots) cover(s) the twelve (12) month duration of the proposed modification period of the Framework Agreement. (SC Ref:756349)

Reference

FTS 003092-2024